JAZZ PHARMACEUTICALS PLC

NASDAQ: JAZZ (Jazz Pharmaceuticals plc)

Last update: 07 Nov, 6:32PM

234.76

7.44 (3.27%)

Previous Close 227.32
Volume 886,982
Price / Earnings (Forward) 10.29
Price / Sales 3.40
Price / Book 3.68
52 Weeks Range
132.10 (-43%) — 266.38 (13%)
Profit Margin 11.86%
Operating Margin (TTM) -2.90%
Diluted EPS (TTM) 7.37
Quarterly Revenue Growth (YOY) -0.50%
Quarterly Earnings Growth (YOY) 103.00%
Total Debt/Equity (MRQ) 129.82%
Current Ratio (MRQ) 3.38
Operating Cash Flow (TTM) 1.56 B
Levered Free Cash Flow (TTM) 1.50 B
Return on Assets (TTM) 3.99%
Return on Equity (TTM) 12.25%

AIStockmoo Score

0.0
The price implies earnings growth of 22.7% a year; the business can fund about 12.3% a year. info
High debt. Ample short-term liquidity. Positive cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Valuation History info NA
Return on Capital info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
Uptrend over the past year. Trading near its 52-week high. info
In an uptrend, but its moving averages have flattened. Volume is heavier on up days. A recent move above resistance has not been confirmed. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Holdings' Sentiment info NA
News Mood info NA
Insiders net selling recently. info
Institutional Flow info NA
Short Interest info NA
Market environment cautious. info
Sector lagging the market.
The pillars disagree, so the score is softened.
Priced low for its earnings growth. info
Near its medium-term trend line. info
Price is high against its 52-week average. Up over 5 years. info
Trend up on all three terms. Short-term momentum rising. info
Price is between support and resistance. info
Final Score -0.01
Show all

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Jazz Pharmaceuticals plc Mixed Bullish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
JAZZ - - - 3.68 0.0
HLVX 103 M - - 0.710 0.0
IPA 96 M - - 5.98 -0.5
MEIP 49 M - - - 0.0
SONN 33 M - - 2.07 -1.4
OMER - - - - -1.2

Select this tab to load the latest available analysis.

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value
% Held by Insiders 3.04%
% Held by Institutions 101.22%

No data within this time range.

Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
COZADD BRUCE C - 234.76 -68,808 -16,153,366
Aggregate Net Quantity -68,808
Aggregate Net Value ($) -16,153,366
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 234.76
Name Holder Date Type Quantity Price Value ($)
COZADD BRUCE C Director 06 Nov 2026 Sell (-) 68,808 234.76 16,153,366
COZADD BRUCE C Director 06 Nov 2026 Option execute 86,500 - -

Recent Signals candle patterns and EMA crosses

▲ Bullish EMA cross 2 sessions ago · 16 Nov
Medium term · EMA 20/50
The 20-day EMA crossed above the 50-day: the medium-term trend turned up.

Technical Setup Medium

Trend order
Slope –
Entry –
Volume
In an uptrend, but its moving averages have flattened. Volume is heavier on up days. A recent move above resistance has not been confirmed.
Nearest support: 246.60 – 252.34 · strong level
Nearest resistance: 253.35 – 258.77 · moderate level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria